The NIH will be awarding up to $150 million over 5 years to four companies who are developing drug treatments that could be effective against bioterrorist attacks.
United Therapeutics is working on a broad-spectrum drug called UV-4 for dengue and the flu, which might also combat the issue of drug resistance.
The drug company CUBRC is developing a tetracycline that could treat community-acquired pneumonia and other respiratory diseases. There are also plans on testing this drug against Bacillus anthracis and Yersinia pestis, which cause anthrax and the plague, respectively, and are bioterror possibilities.
Entana Pharmaceuticals is working on broad-spectrum antibiotics called bicyclolides. These are effective against both gram positive and gram negative strains of bacteria, and have shown promise against anthrax, plague, and tularemia.
XOMA LLC (from Berkeley!) is contracted to develop an intravenous botulism poisoning treatment.
--Sarah Kaewert
http://www.cidrap.umn.edu/cidrap/content/bt/bioprep/news/oct1411spectrum.html
Subscribe to:
Post Comments (Atom)
1 comment:
I was scrolling through a binary option group ,then i saw a post by Robert Seaman about Forex and binary trading and how i could earn much more than i can imagine, i got in touch with him and he made every step clear to me and how his strategy would work magic. and it really did!! i got $16k my first week after i invested just $750 if you are having difficulties in trading, she can also manage your broker account,which you will also have your ACCESS LOGIN so as to enable you to check your trade records and balance daily contact Sir Robert through Email: Robertseaman939@gmail.com
Post a Comment